Top 10 Osseointegration Implants Companies

Why the Osseointegration Implants Market Is Expanding

The Global Osseointegration Implants Market is projected to grow from USD 6.8 billion in 2024 to USD 11.4 billion by 2032, registering a CAGR of 6.7% during the 2024–2032 forecast period. Market Research Future identifies three structural demand engines sustaining above-baseline growth: the accelerating global burden of edentulism and dental disorders (affecting over 3.5 billion people worldwide per WHO estimates), the demographic shift toward aging populations requiring orthopedic and dental reconstruction, and the technological convergence of digital dentistry, 3D-printed patient-specific implants, and bioactive surface modifications that improve bone-to-implant integration kinetics.

Dental implants account for the greatest share of the application category, with a market share of about 58%. The partial and full edentulism in the population aged 55 years and above is the basis for the dental implant segment. The fastest-growing application segment is orthopedic osseointegration implants due to the increase in trauma cases, increasing volume of joint replacements, and increasing use of osseointegrated prosthetic limbs for amputee rehabilitation.

Titanium is the leading material by volume, making up more than 65% of the total due to its long-standing biocompatibility profile and modulus of elasticity close to that of human bone. However, zirconia and ceramic composites are the fastest-growing sub-segment in materials, as the rise of aesthetic dentistry and metal sensitivity concerns are pushing dentists to use tooth-colored, hypoallergenic alternatives. Dental clinics and hospitals together constitute 72% of demand by end-user. Ambulatory surgery centers are the fastest expanding channel with increasing protocol acceptance of same-day implant surgeries.

What Structurally Separates Leaders from the Field

MRFR points out 4 major competitive position drivers in osseointegration implants: proprietary surface technology for faster osseointegration timeline and shorter healing period; vertical integration from raw titanium processing to final sterile packaging, managing cost structure and supply security; integration of digital workflow from intraoral scanning to CAD/CAM surgical guides and implant-prosthetic ecosystem connectivity; regulatory breadth with FDA, CE and NMPA approvals for multiple product generations, allowing unrestricted market access. And the combination of surface-science differentiation and end-to-end digital treatment planning is enabling firms to win premium pricing and clinician loyalty, at the expense of commoditized, first-generation implant manufacturers.

Top 10 Global Osseointegration Implants Companies --- MRFR Rankings (2026)

MRFR has identified and profiled the following leading osseointegration implant companies globally, evaluated on the basis of revenue performance, geographic presence, technology strategy, innovation investment, and clinical evidence base. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of June 2026.

Revenue figures are drawn from SEC filings and official investor disclosures where the company is publicly traded; figures for private companies are marked as undisclosed. Segment-specific revenue is cited where separately disclosed; otherwise total company revenue is provided with the segment estimated where calculable. Validation notes are included in brackets above.

Detailed Company Profiles

1. Straumann Group | SIX: STMN | Basel, Switzerland

Straumann Group commands the premium tier of global dental implantology through a vertically integrated model spanning implant R&D, biomaterial production, digital workflow hardware (intraoral scanners, CAD/CAM), and proprietary software ecosystems. The company's FY2024 revenue of CHF 2.50 billion reflects a diversified portfolio where implants and related products constitute the majority, supplemented by orthodontics (ClearCorrect) and digital equipment (Dental Wings, CARES). 

Straumann's 2024 acquisition of Southern Implants — a South African specialist in immediate-loading and zygomatic implant solutions — filled a critical portfolio gap for complex anatomical cases where traditional implant placement is contraindicated. The Group's BLX implant system, launched with an active hydrophilic surface chemistry, reduces healing protocols from 12 weeks to 6–8 weeks in eligible cases, a clinical speed advantage that commands 15–20% pricing premiums over standard surfaces.

2. Envista Holdings Corporation | NYSE: NVST | Brea, California, USA

Envista operates the dental industry's most extensive brand portfolio, uniting Nobel Biocare (premium implants), Implant Direct (value implants), Ormco (orthodontics), Kerr (restoratives), and DEXIS (diagnostics) under a single corporate structure spun out from Danaher in 2019. The company reported total sales of USD 2.51 billion for FY2024, per its SEC filing. 

The company recorded goodwill and intangible asset impairments of $1,153.8 million in FY2024, reflecting strategic repositioning: Envista is consolidating its implant brands and retreating from low-margin equipment segments to focus on consumable-driven recurring revenue. Nobel Biocare's TiUnite surface and NobelActive implant design remain clinically respected, but Envista's implant market share has eroded in Europe and North America as Straumann and Dentsply Sirona tightened distributor relationships.

3. Zimmer Biomet Holdings | NYSE: ZBH | Warsaw, Indiana, USA

Zimmer Biomet participates in osseointegration implants through two vectors: its dental division (Zimmer Dental, acquired via Biomet 3i) and its dominant orthopedic reconstruction franchise, where osseointegration science underpins hip, knee, and shoulder replacement fixation. The company reported USD 7.68 billion in total FY2024 revenue. Dental segment revenue is not separately disclosed in the 10-K; the ~USD 450 million dental estimate from prior filings remains unverified for FY2024. 

Zimmer Biomet's 2024 acquisition of Embody added collagen-based bioactive implant coatings to its regenerative portfolio, directly addressing the gap between mechanical fixation and biological integration in challenging bone quality cases. The ROSA robotic surgery platform, initially developed for knee replacement, is being adapted for dental implant placement — a crossover that could differentiate Zimmer Biomet in an era of surgical precision demands.

4. Dentsply Sirona | NASDAQ: XRAY | Charlotte, North Carolina, USA

Dentsply Sirona is the world's largest professional dental products manufacturer by revenue, reporting USD 3.79 billion in FY2024 net sales. [VALIDATED: SEC 8-K confirms $3,793 million net sales for FY2024. Original figure is CORRECT.] Its Orthodontic and Implant Solutions segment declined 6.5% year-over-year — a performance drag that contributed to a USD 910 million GAAP net loss driven by USD 870 million in goodwill impairments, including a full write-off of the Byte aligner trademark.

The company's implant heritage traces to the 2011 acquisition of Astra Tech (USD 1.8 billion), whose OsseoSpeed TX surface remains a clinically respected platform. However, Dentsply Sirona's implant segment has suffered from portfolio fragmentation across the Astra Tech, Ankylos, and Xive systems, confusing clinician positioning against Straumann's unified brand architecture.

5. Osstem Implant | KOSDAQ: 048260 | Seoul, South Korea

Company Overview: Osstem Implant is the global volume leader in dental implant fixture sales and the first Korean company to domestically produce implants, transforming South Korea from an implant importer to a global export hub. The company reported KRW 1.32 trillion in consolidated FY2024 sales (approximately USD 975 million), achieving 9% year-over-year growth despite global economic headwinds.

Osstem's 2024 acquisition of Implacil de Bortoli — Brazil's third-largest implant manufacturer with 14% domestic market share and 26.8% share in São Paulo — established a Latin American manufacturing and distribution beachhead that circumvents import tariffs and leverages local regulatory approvals. The company's product architecture spans the TS (tapered), SS (standard), and US (ultrawide) implant lines, with the SM Torx connection system designed for mechanical stability under functional loading.

6. Henry Schein, Inc. | NASDAQ: HSIC | Melville, New York, USA

Henry Schein is the world's largest distributor of dental products, reporting USD 12.67 billion in total FY2024 net sales. [VALIDATED: SEC 10-K confirms $12,673 million net sales for FY2024. Original document stated USD 12.9 billion — this is INCORRECT.] Unlike manufacturers, Schein's osseointegration implant role is channel-control: the company holds exclusive or preferred distribution agreements with multiple implant manufacturers, positioning it as the gatekeeper through which the majority of U.S. dental implants reach clinics.

Schein's Practice Solutions division provides practice management software, patient communication tools, and equipment financing — an ecosystem lock-in that makes implant manufacturers dependent on Schein's shelf space and sales force reach.

7. Medtronic plc | NYSE: MDT | Dublin, Ireland

Medtronic's participation in osseointegration is concentrated in spinal and orthopedic reconstruction rather than dental implants, though its biologics and surface technologies have direct applicability. Total revenue of USD 32.4 billion and Spine & Biologics ~USD 3.1B could not be independently verified from public SEC filings during this review. Medtronic's INFUSE Bone Graft (recombinant human BMP-2) is the most clinically validated osteoinductive biologic for spinal fusion, creating a regulatory and evidence barrier that competitors have failed to breach despite two decades of attempts. 

The StealthStation surgical navigation and Mazor X robotic spine surgery platforms represent the precision-surgery infrastructure that next-generation osseointegrated implants will require for optimal placement. Medtronic's titanium plasma-sprayed (TPS) and porous titanium interbody cages achieve osseointegration rates exceeding 95% at 12 months in pivotal trials, setting the clinical benchmark for spinal implant fixation.

8. Smith+Nephew | LSE: SN | London, UK

Smith+Nephew's orthopedic reconstruction division applies osseointegration science to joint replacement and trauma fixation. [VALIDATED: FY2024 total revenue was USD 5.81 billion ($5,810 million) per 2024 Annual Report. Original document stated USD 5.34 billion — this is INCORRECT.] Orthopaedics revenue was $2,305 million; Sports Medicine & ENT was $1,824 million; Advanced Wound Management was $1,681 million.

The company's JOURNEY II knee system incorporates porous titanium constructs designed for biological fixation rather than cemented attachment, appealing to younger, active patients requiring long-term implant survival. The REDAPT hip revision system addresses failed osseointegration in complex revision scenarios where bone stock deficiency demands modular, customizable implant geometries. Smith+Nephew has invested in 3D-printed titanium manufacturing (via its TRUMATCH personalized solutions) to produce patient-specific implants with lattice architectures that mimic trabecular bone porosity, accelerating bone ingrowth kinetics.

9. Integrum AB | Nasdaq Stockholm: INTEG B | Mölndal, Sweden

Integrum AB is the only company globally with FDA approval for osseointegrated prosthetic limb attachment, representing a narrow but critically important niche in osseointegration science. This small scale reflects the specialized nature of its OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) system. 

OPRA involves direct skeletal attachment of a titanium fixture to the residual limb bone, eliminating socket-related complications (sweating, skin breakdown, poor fit) that afflict 60%+ of lower-limb amputees. Over 400 OPRA surgeries have been performed globally, with the system CE-marked and FDA-cleared for both transfemoral and transtibial applications. Integrum's technology derives from Professor Per-Ingvar Brånemark's original osseointegration research — the same scientific foundation that enabled modern dental implants.

10. DIO Corporation | Private | Busan, South Korea

DIO Corporation is a leading South Korean dental implant manufacturer competing directly with Osstem in the mid-tier global market, operating in 60+ countries with particular strength in China, Southeast Asia, and the Middle East. The company's Navident dynamic navigation system provides real-time surgical guidance without the capital cost of static surgical guide fabrication, lowering the technology barrier for general practitioners entering implantology.

DIO's SM Torx implant features an RBM (resorbable blast media) surface modification and a connection geometry designed for platform-switching protocols that preserve peri-implant bone levels. Unlike Osstem's aggressive M&A strategy, DIO has pursued organic growth through direct subsidiary establishment in target markets, maintaining tighter control over distribution and pricing.

M&A Activity Tracker (2018–2025)

The Osseointegration Implants Market has experienced targeted consolidation as manufacturers sought surface-technology differentiation, digital workflow integration, and geographic expansion in emerging markets. Market Research Future tracks the following verified transactions directly relevant to osseointegration implants.

Key Trend: MRFR analysis identifies surface-technology specialization as the dominant M&A theme in osseointegration implants. Straumann's acquisition of Southern Implants and Zimmer Biomet's acquisition of Embody both target next-generation biological integration capabilities that reduce healing time and expand patient eligibility to compromised bone sites. A parallel theme is emerging-market manufacturing localization: Osstem's Implacil acquisition and Straumann's Brazilian capacity expansion reflect strategic hedging against tariff escalation and currency volatility in high-growth Latin American and Asian markets.

R&D & Innovation Signals

R&D and technology investment across the Osseointegration Implants Market has accelerated as manufacturers compete on biological integration speed, digital workflow integration, and patient-specific geometry optimization — addressing the primary clinical constraints of healing time, surgical precision, and aesthetic outcomes that define competitive differentiation.

• Straumann Group launched the BLX implant system with an active hydrophilic surface chemistry that reduces osseointegration protocols from 12 weeks to 6–8 weeks in eligible cases, commanding 15–20% pricing premiums and shifting clinician preference toward immediate-loading protocols that reduce chair time and patient visits.

• Envista Holdings recorded USD 1.15 billion in goodwill and intangible asset impairments in FY2024, including a full write-off of the Byte aligner trademark, signaling strategic retreat from orthodontia-implant convergence bets and refocusing on core implant-prosthetic workflows.

• Zimmer Biomet is adapting its ROSA robotic surgery platform from knee replacement into dental implant placement, leveraging orthopedic precision-navigation infrastructure to differentiate in an era where surgical accuracy increasingly determines implant survival rates and restorative outcomes.

• Osstem Implant invested KRW 805 million in R&D (non-consolidated, FY2024) and maintains a 9.4% R&D investment rate, focused on digital dentistry integration and surface modification; the company's OIC Education Center conducted 636 Master Course seminars in 2024, creating clinician dependency that locks in implant system selection.

• Dentsply Sirona's Orthodontic and Implant Solutions segment declined 6.5% in FY2024, with competitive pressure in implants and a USD 370 million Q4 2024 impairment of Byte aligner assets; the company's ~4% R&D rate and 300,000+ annual clinician training engagements represent defensive investments to retain share against integrated competitors.